Suspension for oral administration comprising amorphous tolvaptan

This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan fro...

Full description

Saved in:
Bibliographic Details
Main Authors SUZUKI, KAI, NAKAMURA, ATSUYA, AKAGI, AKITSUNA, NISHIBAYASHI, TORU
Format Patent
LanguageChinese
English
Published 01.06.2019
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

Abstract This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan from the gastrointestinal tract; and a solid formulation for oral administration that can be suspended to prepare the suspension for oral administration at the time of use. This invention relates to a suspension for oral administration, in particular, a syrup, comprising (a) particles containing amorphous tolvaptan, (b) hydroxypropyl methylcellulose (HPMC), and (c) a solvent, wherein the amount of the HPMC (b) is 0.1 to 25% by weight based on the total weight of the suspension for oral administration.
AbstractList This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan from the gastrointestinal tract; and a solid formulation for oral administration that can be suspended to prepare the suspension for oral administration at the time of use. This invention relates to a suspension for oral administration, in particular, a syrup, comprising (a) particles containing amorphous tolvaptan, (b) hydroxypropyl methylcellulose (HPMC), and (c) a solvent, wherein the amount of the HPMC (b) is 0.1 to 25% by weight based on the total weight of the suspension for oral administration.
Author AKAGI, AKITSUNA
NAKAMURA, ATSUYA
SUZUKI, KAI
NISHIBAYASHI, TORU
Author_xml – fullname: SUZUKI, KAI
– fullname: NAKAMURA, ATSUYA
– fullname: AKAGI, AKITSUNA
– fullname: NISHIBAYASHI, TORU
BookMark eNqNyk0KwkAMQOFZ6MK_O-QCgqBUt1YUXVtwWUJN68BMEiap5xfBA7h68PHmYcLCNAvH-2hKbFEYeikgBRPgM0eO5gX9651kLdEiD4BZir5kNHBJb1RHXoZpj8lo9esiwOXcnK5rUmnJFDti8rZ53Kpqs98d6nr7x_IBU1c00g
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID TWI660748BB
GroupedDBID EVB
ID FETCH-epo_espacenet_TWI660748BB3
IEDL.DBID EVB
IngestDate Fri Jul 19 13:05:23 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language Chinese
English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_TWI660748BB3
Notes Application Number: TW20143106839
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190601&DB=EPODOC&CC=TW&NR=I660748B
ParticipantIDs epo_espacenet_TWI660748BB
PublicationCentury 2000
PublicationDate 20190601
PublicationDateYYYYMMDD 2019-06-01
PublicationDate_xml – month: 06
  year: 2019
  text: 20190601
  day: 01
PublicationDecade 2010
PublicationYear 2019
RelatedCompanies OTSUKA PHARMACEUTICAL CO., LTD
RelatedCompanies_xml – name: OTSUKA PHARMACEUTICAL CO., LTD
Score 3.3145502
Snippet This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of...
SourceID epo
SourceType Open Access Repository
SubjectTerms HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title Suspension for oral administration comprising amorphous tolvaptan
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190601&DB=EPODOC&locale=&CC=TW&NR=I660748B
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8NADA9zivqmU3F-cQ_St2K7a7v2oQj9Ygr7QKrb20i7KxO0La5T8K83Vzc_HvTtuIOQCyS_JJfkAC7NRNeR26mqZXqmGoiaihxNNeEZdjPDsnUhE_r9gdW7N24n5qQB83UvTD0n9K0ejkgalZK-V7W9Lr-TWEFdW7m4Sh5pq7iOYjdQVtExoRsFGErgueFoGAx9xffdeKwM7twbyyKwtL0N2JROtJyyHz54siel_Ako0R5sjYhWXu1D433egh1__e9aC7b7q-duWq40b3FA5m-5KGWxeZEz8jOZbKxn-GvyLZPl4aSzBEYMnwsSIEX1rCqeXrEkF_AQWBTGfk8lXqZf157G4zXTHj-CZl7k4hhYBzvC0VMbnY4wHI4J7wrD1oQwu8lshrwN7T_JnPxzdgq7Un6fVVBn0KxeluKc8LZKLmpRfQAs4ohu
link.rule.ids 230,309,786,891,25594,76906
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8NADA9zivNNp-L8vAfpW3Hd9WsPRWi7sem-kOr2NtLuygRti-sU_OvN1c2PB3077iDkAskvySU5gEsj1DTkdqTWYy1WdcS6ihwNNeQxWrFu2pqQCf3-wOzc6zcTY1KC-boXppgT-lYMRySNikjf88JeZ99JLL-orVxchY-0lV63A8dXVtExoRsFGIrvOq3R0B96iuc5wVgZ3Dld0ySwtN0N2LTkbF7pOD24sicl-wko7V3YGhGtJN-D0vu8ChVv_e9aFbb7q-duWq40b7FP5m-5yGSxeZow8jOZbKxn-GvyLZPl4aSzBEYMn1MSIEX1LE-fXjEjF_AAWLsVeB2VeJl-XXsajNdMu_wQykmaiCNgDWyIphbZ2GwIvckx5JbQ7boQhhXOZshrUPuTzPE_ZxdQ6QT93rTXHdyewI6U5WdF1CmU85elOCPszcPzQmwfttaLWw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Suspension+for+oral+administration+comprising+amorphous+tolvaptan&rft.inventor=SUZUKI%2C+KAI&rft.inventor=NAKAMURA%2C+ATSUYA&rft.inventor=AKAGI%2C+AKITSUNA&rft.inventor=NISHIBAYASHI%2C+TORU&rft.date=2019-06-01&rft.externalDBID=B&rft.externalDocID=TWI660748BB